Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.

MLA

Bonneterre, Jacques, et al. “Long-Term Cardiac Follow-up in Relapse-Free Patients after Six Courses of Fluorouracil, Epirubicin, and Cyclophosphamide, with Either 50 or 100 Mg of Epirubicin, as Adjuvant Therapy for Node-Positive Breast Cancer: French Adjuvant Study Group.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 22, no. 15, Aug. 2004, pp. 3070–79. EBSCOhost, https://doi.org/10.1200/JCO.2004.03.098.

APA

Bonneterre, J., Roché, H., Kerbrat, P., Fumoleau, P., Goudier, M.-J., Fargeot, P., Montcuquet, P., Clavère, P., Barats, J.-C., Monnier, A., Veyret, C., Datchary, J., Van Praagh, I., & Chapelle-Marcillac, I. (2004). Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 22(15), 3070–3079. https://doi.org/10.1200/JCO.2004.03.098

Chicago

Bonneterre, Jacques, Henri Roché, Pierre Kerbrat, Pierre Fumoleau, Marie-Josèphe Goudier, Pierre Fargeot, Philippe Montcuquet, et al. 2004. “Long-Term Cardiac Follow-up in Relapse-Free Patients after Six Courses of Fluorouracil, Epirubicin, and Cyclophosphamide, with Either 50 or 100 Mg of Epirubicin, as Adjuvant Therapy for Node-Positive Breast Cancer: French Adjuvant Study Group.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 22 (15): 3070–79. doi:10.1200/JCO.2004.03.098.